| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 05/23/2006 | US7049312 2H-1,4-benzothiazin-3(4H)-one derivative as anticarcinogenic and antiproliferative agent; inhibitors of serine/threonine and tyrosine kinase activity |
| 05/23/2006 | US7049310 Therapy for bacteria infections |
| 05/23/2006 | US7049306 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4. |
| 05/23/2006 | US7049300 C-glycoside compounds for stimulating the synthesis of glycosaminoglycans |
| 05/23/2006 | US7049296 For therapy and prophylaxis of Alzheimer's disease |
| 05/23/2006 | US7049295 Compounds and use thereof to modify transport across cell membranes |
| 05/23/2006 | US7049119 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/23/2006 | US7049117 Comprises chimeric polypeptide associated with uracil phosphoribosyl transferase (UPRTase) treating proliferative and infectious diseases; gene therapy; antiproliferative agents; suicide genes |
| 05/23/2006 | US7049059 Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression |
| 05/23/2006 | US7048954 Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles |
| 05/23/2006 | US7048932 Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor |
| 05/23/2006 | US7048924 Combination antiviral and interleukin-2 therapy for HIV infection |
| 05/23/2006 | US7048909 Aerosols containing nondegraded atenolol, pindolol, esmolol, propranolol, or metoprolol |
| 05/23/2006 | US7048908 Particles for inhalation having sustained release properties |
| 05/23/2006 | CA2411766C Non-nucleoside reverse transcriptase inhibitors |
| 05/23/2006 | CA2339630C Carboline derivatives as cgmp phosphodiesterase inhibitors |
| 05/23/2006 | CA2173747C Calcium receptor-active arylalkyl amines |
| 05/18/2006 | WO2006052569A1 Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists |
| 05/18/2006 | WO2006052026A1 Acid salt of benzimidazole derivative and crystal thereof |
| 05/18/2006 | WO2006052013A1 Thienopyrrole compounds and utilization thereof as hcv polymerase inhibitor |
| 05/18/2006 | WO2006051997A1 Cystein dioxygenase inducer |
| 05/18/2006 | WO2006051951A1 REMEDY FOR DIABETES CONTAINING Cdk5 INHIBITOR |
| 05/18/2006 | WO2006051946A1 Novel polypeptide having protease inhibitory activity |
| 05/18/2006 | WO2006051826A1 Nitrogenous heterocyclic compound and pharmaceutical use thereof |
| 05/18/2006 | WO2006051808A1 Hsp90 FAMILY PROTEIN INHIBITORS |
| 05/18/2006 | WO2006051773A1 Agent for recovery from cerebral fatigue |
| 05/18/2006 | WO2006051704A1 Imine compound |
| 05/18/2006 | WO2006051662A1 Thiazole derivative |
| 05/18/2006 | WO2006051341A1 Isotopically marked quinoline derivatives as adenosin a3 receptor ligands |
| 05/18/2006 | WO2006034341A3 Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| 05/18/2006 | US20060107339 Transgenic cell comprising human leukocyte antigen binding peptide for use as tools diagnosis, prevention and treatment of cell proliferative disorders; genetic vaccines |
| 05/18/2006 | US20060106116 Composition for lessening oxidative stress |
| 05/18/2006 | US20060106114 Tertiary amino compounds having opioid receptor affinity |
| 05/18/2006 | US20060106102 Napththalene derivatives which inhibit the cytokine or biological activity of microphage migration inhibitory factor (mif) |
| 05/18/2006 | US20060106090 Cytotoxic agents comprising taxanes and their therapeutic use |
| 05/18/2006 | US20060106087 Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative |
| 05/18/2006 | US20060106082 N-[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenylsulfonyl]-4-nitrooxybutanamide, used for the treatment of inflammatory, cardiovascular, gastrointestinal, respiratory and nervous system disorders, as analgesics, antipyretics and antocoagulants or for organ and tissue preservation |
| 05/18/2006 | US20060106075 Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity |
| 05/18/2006 | US20060106072 Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
| 05/18/2006 | US20060106067 Androgen receptor agonist; prostate cancer, hypogonadism; 4-[4-(hydroxymethyl)-1-piperidinyl]-1-naphthonitrile; 4-(4-hydroxy-2-methyl-1-pyrrolidinyl-1-benzothiophene-7-carbonitrile |
| 05/18/2006 | US20060106057 Stabilization of quinapril using magnesium oxide |
| 05/18/2006 | US20060106056 Novel quinuclidine derivatives and medicinal compositions containing the same |
| 05/18/2006 | US20060106055 Novel quinuclidine derivatives and medicinal compositions containing the same |
| 05/18/2006 | US20060106054 Phosphodiesterase 10a inhibitors |
| 05/18/2006 | US20060106050 Thrombin receptor antagonists |
| 05/18/2006 | US20060106048 Furoisoquinoline derivative and use thereof |
| 05/18/2006 | US20060106046 2-(3,4-difluorophenyl)-N-methyl-2-(1H-1,2,3-triazol-1-yl)-N-[3-(spiro[isobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]acetamide, used for preventing or treating cardiovascular, nervous, metabolic, reproductive, respiratory and/or digestive system disorders |
| 05/18/2006 | US20060105997 Mitotic kinesin inhibitors |
| 05/18/2006 | US20060105990 Uronic acid-terminated carbohydrate having a double bond between the C4 and C5 atom of the uronic acid a maximum degree of polymerization of 100, combined with a mixture of two different undigestable prebiotic carbohydrates; blocking the adhesion of pathogens or toxins to eucariotic cells |
| 05/18/2006 | US20060105969 Anthelmintic compositions |
| 05/18/2006 | US20060105957 Loop peptide and TGFalpha for stimulating stem cell proliferation and migration |
| 05/18/2006 | US20060105430 cleaving a heparin-like glycosaminoglycan using modified heparinases having altered binding specificity and activity; angiogenesis inhibition |
| 05/18/2006 | US20060105429 Nucleic acid encoding protein which comprises hormone and has higher plasma stability; maintains biological activity for prolonged period in body |
| 05/18/2006 | US20060105423 Microorganisms as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors |
| 05/18/2006 | US20060105386 17867, a novel human aminopeptidase |
| 05/18/2006 | US20060105048 Remedy |
| 05/18/2006 | US20060105013 Osteopontin-coated surfaces and methods of use |
| 05/18/2006 | US20060104998 e.g. 2-Amino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-7-methyl-4H-pyrrolo [2,3-h]chromene; antiproliferative, antitumor, anticarcinogenic agent |
| 05/18/2006 | US20060104947 Remedy for pemphigoid |
| 05/18/2006 | US20060104926 Whitening agent, skin preparation for external use and cosmetic |
| 05/18/2006 | DE102004054552A1 Neue Zusammensetzung zur Erleichterung der Humangeburt New composition to facilitate human childbirth |
| 05/18/2006 | CA2588073A1 Isotopically marked quinoline derivatives as adenosin a3 receptor ligands |
| 05/18/2006 | CA2587667A1 Imine compound |
| 05/18/2006 | CA2584225A1 Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists |
| 05/17/2006 | EP1657954A1 Transmitter of wireless microphone, receiver for wireless microphone, mobile information communication apparatus, and communication system for wireless microphone |
| 05/17/2006 | EP1657247A1 Steroidal compounds for inhibiting steroid sulphotase |
| 05/17/2006 | EP1657242A1 Imidazopyridine derivatives |
| 05/17/2006 | EP1657238A1 Fused pyrimidine derivative and use thereof |
| 05/17/2006 | EP1657233A1 Lipoxin compounds |
| 05/17/2006 | EP1656952A2 Polymer conjugates of interferon beta-1A and uses thereof |
| 05/17/2006 | EP1656948A1 Osteogenesis promoter |
| 05/17/2006 | EP1656943A1 Extract from plant of japanese parsley family and process for producing the same |
| 05/17/2006 | EP1656940A1 Angiotensin II receptor antagonists for treating vascular headache conditions |
| 05/17/2006 | EP1656936A1 Macrophage activation inhibitor |
| 05/17/2006 | EP1656368A2 Substituted hertocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| 05/17/2006 | EP1656123A2 Anti-candida agents for the treatment of prion diseases |
| 05/17/2006 | EP1558252A4 Substituted furo 2,3-b| pyridine derivatives |
| 05/17/2006 | EP1543003B1 Imidazo¬1,2-a|pyridines |
| 05/17/2006 | EP1450782B9 Use of a combination composition comprising propionyl l-carnitine and further drugs for the treatment of erectile dysfunction |
| 05/17/2006 | EP1423391B1 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases |
| 05/17/2006 | EP1362047B1 Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| 05/17/2006 | EP1349864B1 Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases |
| 05/17/2006 | EP1345929B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/17/2006 | EP1345927B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/17/2006 | EP1345926B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/17/2006 | EP1345925B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/17/2006 | EP1330293B1 Controlled release composition comprising lactic acid polymer, and method of producing the same |
| 05/17/2006 | EP1317452B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/17/2006 | EP1317447B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/17/2006 | EP1307202B1 Method for the treatment of overactive bladder |
| 05/17/2006 | EP1231983B1 Combination of dhea and calcitonin for the treatment of subnormal bone mineral density |
| 05/17/2006 | EP1229894B1 Cosmetic compositions containing chick pea extract and retinoids |
| 05/17/2006 | EP1214409B1 Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity |
| 05/17/2006 | EP1204652B1 Novel succinate derivative compounds useful as cysteine protease inhibitors |
| 05/17/2006 | EP1141235B1 (bifidobacterium) in the treatment of inflammatory disease |
| 05/17/2006 | EP1140881B1 Antithrombotic amides |
| 05/17/2006 | EP1135411B1 Methods and compositions for treating disorders involving excitotoxicity |
| 05/17/2006 | EP1114035B1 Quinazoline derivatives and pharmaceutical applications thereof |
| 05/17/2006 | EP1109787B1 Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
| 05/17/2006 | EP0937077B1 Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy |